Zealand Pharma partners with Generate in $1B obesity treatment deal

Generate: Generate Biomedicines Inc. is a biotechnology company that employs a generative AI platform integrated with experimental validation to design novel multispecific protein therapeutics. The company recently went public and focuses on engineering proteins with tailored biological functions across therapeutic areas. In this news, Generate is partnering with Zealand Pharma to apply its platform specifically to obesity and metabolic disease programs, leading early research stages while Zealand handles later development and commercialization. Zealand Pharma: Zealand Pharma A/S is a Danish biotechnology company focused on developing peptide-based therapeutics targeting metabolic diseases such as obesity and related conditions. The firm is expanding its capabilities beyond peptides through external partnerships. In this news, Zealand is collaborating with Generate Biomedicines to co-develop AI-engineered protein therapeutics for obesity and other metabolic disorders. AI Platform Expansion: Generate Biomedicines is extending its generative AI technology into metabolic diseases through strategic collaborations that leverage partner expertise in specific therapeutic areas. Metabolic Drug Modalities: Zealand Pharma is broadening its development approach to include protein therapeutics engineered via AI in addition to its established peptide capabilities for metabolic health.